The latest market price and trend of dasatinib in 2025

Dasatinib (Dasatinib), as a second-generation tyrosine kinase inhibitor for the treatment of chronic myeloid leukemia (CML) and acute lymphoblastic leukemia (ALL), has been fully launched in the domestic market and has been included in the National Medical Insurance Drug List. Although the drug is covered by medical insurance policies and reduces certain financial burdens for patients, the price of its original drug is still relatively high. According to current market price estimates, each box of dasatinib (usually 50mg or 100mg, based on monthly dosage) is priced at around several thousand yuan. The specific price will fluctuate depending on regional policies and hospital levels.

In terms of medical insurance reimbursement, dasatinib has been included in the scope of national medical insurance negotiations. Some regions implement a higher proportion of reimbursement policies, and the patient out-of-pocket ratio is below 30%. However, the reimbursement ratio and upper limit still depend on local medical insurance policy details. Therefore, it is recommended to consult the hospital or designated pharmacy for the actual drug purchase price. In addition, some patients can further reduce treatment costs through critical illness assistance, local subsidies or commercial insurance, which will contribute to the sustainability of long-term medication.

In the international market, India, as a major producer of generic drugs, has launched a number of generic versions of dasatinib, such as the generic drugs produced by Mylan (Mylan) and Natco (NATCO). The therapeutic ingredients and effects are similar to the original drugs, but the prices are more affordable. Currently, the price of this type of generic drugs in India or through cross-border pharmacy sales channels is about 500 to 600 yuan per month, which has attracted the attention of some domestic patients. Although this type of generic drugs has not been officially registered and marketed in mainland China, some patients will obtain it through formal channels or overseas medical cooperation institutions.

From the overall trend, 2025 The price of dasatinib will still remain at a high level. Although medical insurance coverage has alleviated the financial pressure of some patients, there is still a significant price difference compared with the Indian generic version. In the future, if the country promotes the import of more high-quality generic drugs or the listing of domestic generic drugs, the price of dasatinib is expected to gradually decrease. At the same time, with the emergence of more targeted therapeutic drugs and intensifying market competition, patients will have more treatment options. For patients with long-term medication needs, paying attention to medical insurance trends, rationally choosing drug purchase channels, and combining doctor's advice are still the key ways to ensure efficacy and reduce burden.

Reference materials:https://www.drugs.com/